----
Current ValuationThe current P/E ratio is -44.99, within the reasonable range, cheaper than 51.72% of the time in the past 1 years, and the industry ranks 51/58, the industry Median -2.25.
-44.99xP/E
$63.81Stock price
$-1.42Earnings per share
-44.99xP/E
Stock price$63.81Earnings per share$-1.42
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -43.68x
- Typical range
- -58.27x–-32.22x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
010203040
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x40x80x120x160x200x
| Name/Symbol | |||
|---|---|---|---|
LZAGYUSLonza | -389.05x | -- | $53.56B |
CRLUSCharles River Laboratorie | -68.00x | 242.15% | $16.21B |
AVTRUSAvantor | -20.07x | 144.28% | $11.60B |
TEMUSTempus AI | -44.99x | 1.11% | $11.45B |
TXGUS10X Genomics | -120.97x | 108.91% | $9.09B |
BRKRUSBruker | -81.68x | 7.71% | $8.73B |
ADPTUSAdaptive Biotechnologies | -61.01x | 38.37% | $3.90B |
ABCLUSAbcellera Biologics | -22.38x | 36.29% | $3.68B |
FTREUSFortrea | -26.70x | 93.77% | $2.27B |
ALMRUSAlamar Biosciences | -41.53x | 80.56% | $2.06B |
MRVIUSMaravai LifeSciences | -23.72x | 64.44% | $1.84B |
PSNLUSPersonalis | -15.76x | 18.96% | $1.69B |
AZTAUSAzenta | -12.84x | 177.69% | $1.58B |
CYRXUSCryoport | -19.90x | 156.25% | $903.07M |
CTKBUSCytek Biosciences | -8.76x | 33.98% | $705.81M |
OABIUSOmniAb | -15.70x | 35.96% | $694.97M |
DNAUSGinkgo Bioworks | -2.25x | 35.20% | $653.87M |
PACBUSPacific Biosc California | -4.87x | 75.69% | $640.31M |
EVOUSEvotec SE | -2.40x | 385.41% | $547.02M |
NAUTUSNautilus Biotechnology | -5.85x | 9.04% | $330.86M |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
